10-Valent pneumococcal non-typeable H. influenzae protein D conjugate vaccine (PHiD-CV10) versus 13-valent pneumococcal conjugate vaccine (PCV13) as a booster dose to broaden and strengthen protection from otitis media (PREVIX_BOOST) in Australian Aboriginal children: study protocol for a randomised controlled trial

  • Victor Oguoma
  • , Nicole Wilson
  • , Kim Mulholland
  • , Mathuram Santosham
  • , Paul Torzillo
  • , Peter McIntyre
  • , Heidi C Smith-Vaughan
  • , Anne Balloch
  • , Mark Chatfield
  • , Deborah Lehmann
  • , Michael J Binks
  • , Anne B Chang
  • , Jonathan Carapetis
  • , Vicki Krause
  • , Ross Andrews
  • , Tom Snelling
  • , Paul Licciardi
  • , Peter S. Morris
  • , Amanda Jane Leach

Research output: Contribution to journal › Article › peer-review

3   Link opens in a new tab Citations (Scopus)
73 Downloads (Pure)

Fingerprint

Dive into the research topics of '10-Valent pneumococcal non-typeable H. influenzae protein D conjugate vaccine (PHiD-CV10) versus 13-valent pneumococcal conjugate vaccine (PCV13) as a booster dose to broaden and strengthen protection from otitis media (PREVIX_BOOST) in Australian Aboriginal children: study protocol for a randomised controlled trial'. Together they form a unique fingerprint.
Sort by

Keyphrases

Medicine and Dentistry

Immunology and Microbiology

Pharmacology, Toxicology and Pharmaceutical Science